FDA Proposes Excluding Semaglutide and Other Peptides from Clinical Need List
In a recent notice published in the Federal Register, the Food and Drug Administration (FDA) has proposed excluding several peptides, including semaglutide and liraglutide, from the list of bulk drug substances for which there is a clinical need under Section 503B of the Federal Food, Drug, and Cosmetic Act. This decision could impact how these medications are compounded in outsourcing facilities.
Background
The FDA regularly reviews nominations for inclusion on its 503B Bulks List to ensure that active pharmaceutical ingredients (APIs) with significant clinical demand can be used by outsourcing facilities without violating federal regulations. Outsourcing facilities, under Section 503B of the FDCA, are allowed to compound sterile preparations and non-sterile preparations if they meet specific requirements set forth by the FDA.
The process involves evaluating substances based on their clinical need, safety, and efficacy in treating various conditions. The FDA considers nominations for inclusion or exclusion after reviewing public comments and scientific data submitted by stakeholders. This recent announcement highlights a significant shift in how certain peptides are viewed within the regulatory framework.
Key Details
According to the notice published on May 1, 2026, the FDA has identified three bulk drug substances—semaglutide, tirzepatide, and liraglutide—as those that will not be included on the 503B Bulks List. These peptides are widely used in treating type 2 diabetes and obesity due to their effectiveness in lowering blood sugar levels and promoting weight loss.
The FDA's decision is based on several factors, including existing market availability of these drugs through conventional manufacturing processes. The agency also considered safety data indicating that compounding these substances might not be feasible or advisable without additional regulatory oversight.
Other bulk drug substances nominated for inclusion are still under consideration, with the possibility of future updates from the FDA regarding their status on the list.
Key Takeaways
- Semaglutide and Liraglutide Excluded: The FDA has proposed excluding semaglutide and liraglutide from the 503B Bulks List.
- No Immediate Impact on Availability: This decision does not mean these drugs will become less accessible; they remain available through conventional manufacturing processes.
- Regulatory Oversight: Compounding of excluded peptides may face stricter regulations or be prohibited entirely in certain circumstances.
- Potential for Future Updates: The FDA is still reviewing other substances and future updates could impact the list.
What This Means
For peptide researchers, clinicians, and informed consumers, this development underscores the importance of understanding regulatory frameworks governing compounded medications. While the exclusion of semaglutide, tirzepatide, and liraglutide may limit their availability through compounding facilities, these drugs remain accessible through traditional pharmaceutical manufacturing.
The FDA's decision highlights the need for continued dialogue between regulatory bodies, healthcare providers, and researchers to ensure that patients have access to safe and effective treatments. Peptide therapy remains a crucial area of research and clinical application, and stakeholders should stay informed about updates to regulatory guidelines affecting compounded medications.
---
Source: [Federal Register](https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal) — Published 2026-05-01
This article is for informational purposes only and does not constitute medical advice.